“Negative Outcomes from Delaying High-Efficacy Drugs in Relapsing-Remitting Multiple Sclerosis Patients”

https://pubmed.ncbi.nlm.nih.gov/38112646

Delaying escalation of therapy to high-efficacy drugs in relapsing-remitting multiple sclerosis patients who have not responded to initial treatment results in worse clinical and radiological outcomes, including increased disability and more new lesions on MRI.